CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 34 enrolled
Drug / intervention
cisplatin +3 moredrug
Likely dose
Not stated in record
Key inclusion· 7
  • ✓Diagnosis of peripheral T-cell non-Hodgkin's lymphoma
  • ✓Newly diagnosed, relapsed, or progressing disease after 1 prior non-platinum-based chemotherapy (e.g., CHOP)
  • ✓Bulky stage II or stage III or IV disease
  • ✓Bidimensionally measurable disease
Key exclusion· 8
  • ✕T-cell prolymphocytic leukemia, T-cell large granular lymphocytic leukemia, NK-cell leukemia, adult T-cell leukemia/lymphoma, mycosis fungoides/Sézary syndrome
  • ✕Lymphomatoid papulosis, nasal-type extranodal NK/T-cell lymphoma, enteropathy-type T-cell lymphoma, hepatosplenic T-cell lymphoma
  • ✕Subcutaneous panniculitis-like T-cell lymphoma, angioimmunoblastic T-cell lymphoma, primary cutaneous ALCL, ALCL with CD30/ALK/EMA expression
  • ✕Clinical evidence of CNS involvement by lymphoma

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00109928
NCT00109928Phase 2Completed
CompareCT.gov

Phase II Trial of Cisplatin Plus Etoposide Plus Gemcitabine Plus Solumedrol (PEGS) in Peripheral T-Cell Non-Hodgkin's Lymphoma

SWOG Cancer Research Network·interventional·Posted May 4, 2005·Updated Oct 1, 2014

In Brief

A Phase 2 clinical trial evaluating cisplatin, etoposide, and 2 other interventions for Lymphoma. Completed, enrolled 34 participants across 77 sites.

Detailed Summary

RATIONALE: Drugs used in chemotherapy, such as cisplatin, etoposide, gemcitabine, and methylprednisolone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. PURPOSE: This phase II trial is studying how well combination chemotherapy works in treating patients with newly diagnosed stage II, stage III, or stage IV T-cell non-Hodgkin's lymphoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 4, 2005
Enrollment StartSep 1, 2005
Primary CompletionJun 1, 2012
Study CompletionApr 1, 2014
TodayJul 2, 2026
Enrollment to primary: 6.8 yearsPosted 21.2 years ago

Interventions

cisplatindrug

etoposidedrug

gemcitabinedrug

methylprednisolonedrug